Investing.com - Adaptimmune Therapeutics reported on Monday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.04 on revenue of $3.1M. Analysts polled by Investing.com anticipated EPS of $-0.0379 on revenue of $1.4M.
Adaptimmune Therapeutics shares are down 35.9% from the beginning of the year and are trading at $3.455 , down-from-52-week-high.They are under-performing the Nasdaq which is up 15.3% from the start of the year.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
Eli Lilly had missed expectations on August 3 with second quarter EPS of $1.87 on revenue of $6.74B, compared to forecast for EPS of $1.89 on revenue of $6.6B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar